Overview

A Clinical Study to Assess the Efficacy and Safety of DA-3002

Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
A study demonstrates the non-inferiority of DA-3002 when compared with Genotropin®.
Phase:
Phase 3
Details
Lead Sponsor:
Dong-A Pharmaceutical Co., Ltd.
Dong-A ST Co., Ltd.